People · Operator
Named in public records as an officer, director or promoter · active 2016–2022 · Biotech / Pharma, Computers
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Sherlock Biosciences, Inc. | — | Biotech / Pharma | Series C | $112.8M | $1.7B | 2019 |
| iZotope, Inc. | — | Computers | Series A | $14.5M | $83.0M | 2016 |
Issi Rozen at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Issi Rozen on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Michael Rubin | 1 | 8 |
| James Collins | 1 | 8 |
| David Walt | 1 | 6 |
| Laura Witt | 1 | 5 |
| Michael Bayer | 1 | 3 |
| Dean Goodermote | 1 | 2 |
| Mark Ethier | 1 | 2 |
| Rahul Dhanda | 1 | 2 |
| Bryan Dechairo | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.